Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection
Abstract A fixed-dose tablet comprising the NS5A inhibitor ombitasvir, the NS3/4A inhibitor paritaprevir and ritonavir (ombitasvir/paritaprevir/ritonavir) ($ Technivie^{®} $, $ Viekirax^{®} $) is available for use, in combination with ribavirin, for the treatment of chronic hepatitis C virus (HCV) genotype 4 infection. High sustained virological response rates at 12 weeks post-treatment ($ SVR_{12} $) were achieved in treatment-naive or -experienced patients with chronic HCV genotype 4 infection, including patients without cirrhosis who received ombitasvir plus paritaprevir and ritonavir in combination with ribavirin for 12 weeks ($ SVR_{12} $ 100 %) (PEARL-I trial), patients with compensated cirrhosis who received ombitasvir/paritaprevir/ritonavir plus ribavirin for 12 or 16 weeks ($ SVR_{12} $ 97 and 98 %) (AGATE-I trial), or Egyptian patients without cirrhosis who received ombitasvir/paritaprevir/ritonavir plus ribavirin for 12 weeks ($ SVR_{12} $ 94 %) or with compensated cirrhosis who received ombitasvir/paritaprevir/ritonavir plus ribavirin for 12 or 24 weeks ($ SVR_{12} $ 97 and 93 %) (AGATE-II trial). Ombitasvir/paritaprevir/ritonavir was generally well tolerated in patients with chronic HCV genotype 4 infection without cirrhosis or with compensated cirrhosis in clinical trials. There have been postmarketing reports of hepatic decompensation and hepatic failure, which mainly occurred in patients with advanced cirrhosis who received regimens containing ombitasvir/paritaprevir/ritonavir. In conclusion, ombitasvir/paritaprevir/ritonavir is a valuable option for use in patients with chronic HCV genotype 4 infection without cirrhosis or with compensated cirrhosis..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Drugs - 76(2016), 12 vom: 11. Juli, Seite 1203-1211 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Keating, Gillian M. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Breast Cancer Resistance Protein |
| doi: |
10.1007/s40265-016-0612-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR033216983 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR033216983 | ||
| 003 | DE-627 | ||
| 005 | 20230519195037.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40265-016-0612-1 |2 doi | |
| 035 | |a (DE-627)SPR033216983 | ||
| 035 | |a (SPR)s40265-016-0612-1-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.40 |2 bkl | ||
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Keating, Gillian M. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract A fixed-dose tablet comprising the NS5A inhibitor ombitasvir, the NS3/4A inhibitor paritaprevir and ritonavir (ombitasvir/paritaprevir/ritonavir) ($ Technivie^{®} $, $ Viekirax^{®} $) is available for use, in combination with ribavirin, for the treatment of chronic hepatitis C virus (HCV) genotype 4 infection. High sustained virological response rates at 12 weeks post-treatment ($ SVR_{12} $) were achieved in treatment-naive or -experienced patients with chronic HCV genotype 4 infection, including patients without cirrhosis who received ombitasvir plus paritaprevir and ritonavir in combination with ribavirin for 12 weeks ($ SVR_{12} $ 100 %) (PEARL-I trial), patients with compensated cirrhosis who received ombitasvir/paritaprevir/ritonavir plus ribavirin for 12 or 16 weeks ($ SVR_{12} $ 97 and 98 %) (AGATE-I trial), or Egyptian patients without cirrhosis who received ombitasvir/paritaprevir/ritonavir plus ribavirin for 12 weeks ($ SVR_{12} $ 94 %) or with compensated cirrhosis who received ombitasvir/paritaprevir/ritonavir plus ribavirin for 12 or 24 weeks ($ SVR_{12} $ 97 and 93 %) (AGATE-II trial). Ombitasvir/paritaprevir/ritonavir was generally well tolerated in patients with chronic HCV genotype 4 infection without cirrhosis or with compensated cirrhosis in clinical trials. There have been postmarketing reports of hepatic decompensation and hepatic failure, which mainly occurred in patients with advanced cirrhosis who received regimens containing ombitasvir/paritaprevir/ritonavir. In conclusion, ombitasvir/paritaprevir/ritonavir is a valuable option for use in patients with chronic HCV genotype 4 infection without cirrhosis or with compensated cirrhosis. | ||
| 650 | 4 | |a Sustained Virological Response |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Ritonavir |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Breast Cancer Resistance Protein |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Sofosbuvir |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SVR12 Rate |7 (dpeaa)DE-He213 | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs |d Berlin [u.a.] : Springer, 1971 |g 76(2016), 12 vom: 11. Juli, Seite 1203-1211 |w (DE-627)SPR033129762 |w (DE-600)2021165-X |x 1179-1950 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2016 |g number:12 |g day:11 |g month:07 |g pages:1203-1211 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40265-016-0612-1 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 44.40 |q ASE |
| 936 | b | k | |a 44.38 |q ASE |
| 951 | |a AR | ||
| 952 | |d 76 |j 2016 |e 12 |b 11 |c 07 |h 1203-1211 | ||